Adeno-associated virus (AAV) gene therapies have demonstrated clear clinical potential, with multiple products approved globally; however, increasing pipeline complexity and expansion into more prevalent indications are exposing limitations of transient transfection-based manufacturing. Low yields, high costs, process variability, and scaling constraints are emerging as barriers to commercial viability and patient access.
Stable AAV producer cell lines (PCLs) offer a fundamentally different manufacturing paradigm, enabling simplified supply chains, improved batch-to-batch consistency, scalable suspension processes, and the potential for significantly lower production costs. Transitioning from transient transfection to PCL-based manufacturing represents a manufacturing process change that must be assessed through analytical comparability, risk assessment, and, where required, nonclinical or clinical bridging studies in alignment with regulatory expectations. This white paper outlines regulatory frameworks, timing considerations, and analytical strategies for successful PCL adoption, emphasizing the importance of early transition, robust analytics, and proactive engagement with health authorities to minimize development risk and support efficient advancement of AAV gene therapy programs.
